Cite
HARVARD Citation
Leupin, N. et al. (2022). Cusatuzumab for treatment of CD70‐positive relapsed or refractory cutaneous T‐cell lymphoma. Cancer. 128 (5), pp. 1004-1014. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Leupin, N. et al. (2022). Cusatuzumab for treatment of CD70‐positive relapsed or refractory cutaneous T‐cell lymphoma. Cancer. 128 (5), pp. 1004-1014. [Online].